DK1651622T3 - Fremgangsmåde til fremstilling af 2-(quinoxalin-5-ylsulfonylamino)-benzamidforbindelser - Google Patents

Fremgangsmåde til fremstilling af 2-(quinoxalin-5-ylsulfonylamino)-benzamidforbindelser

Info

Publication number: DK1651622T3
Authority: DK; Denmark
Prior art keywords: ylsulfonylamino; quinoxaline; preparation; benzamide compounds; benzamide
Prior art date: 2003-08-08

Application number

DK04780056T

Other languages

English (en)

Inventor

Xiaohu Deng

Chennagiri R Pandit

Jimmy T Liang

Neelakandha Mani

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-08

Filing date

2004-08-04

Publication date

2007-05-07

2004-08-04 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2007-05-07 Application granted granted Critical

2007-05-07 Publication of DK1651622T3 publication Critical patent/DK1651622T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Ceramic Engineering (AREA)
Manufacturing & Machinery (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Inorganic Chemistry (AREA)
Hematology (AREA)
Diabetes (AREA)
Materials Engineering (AREA)
Structural Engineering (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Child & Adolescent Psychology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

DK04780056T 2003-08-08 2004-08-04 Fremgangsmåde til fremstilling af 2-(quinoxalin-5-ylsulfonylamino)-benzamidforbindelser DK1651622T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US49407403P	2003-08-08	2003-08-08
PCT/US2004/025154 WO2005016897A1 (en)	2003-08-08	2004-08-04	Process for the preparation of 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds

Publications (1)

Publication Number	Publication Date
DK1651622T3 true DK1651622T3 (da)	2007-05-07

Family

ID=34193199

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK04780055T DK1651621T3 (da)	2003-08-08	2004-08-04	2-(Quinoxalin-5-ylsulfonylamino)benzamidforbindelser som CCK2-modulatorer
DK04780056T DK1651622T3 (da)	2003-08-08	2004-08-04	Fremgangsmåde til fremstilling af 2-(quinoxalin-5-ylsulfonylamino)-benzamidforbindelser

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK04780055T DK1651621T3 (da)	2003-08-08	2004-08-04	2-(Quinoxalin-5-ylsulfonylamino)benzamidforbindelser som CCK2-modulatorer

Country Status (33)

Country	Link
US (3)	US7288651B2 (da)
EP (2)	EP1651622B1 (da)
JP (2)	JP4818110B2 (da)
KR (1)	KR20060060007A (da)
CN (2)	CN1863781A (da)
AR (1)	AR045930A1 (da)
AT (2)	ATE353322T1 (da)
AU (2)	AU2004265311A1 (da)
BR (1)	BRPI0413449A (da)
CA (2)	CA2534885C (da)
CR (1)	CR8229A (da)
CY (1)	CY1106486T1 (da)
DE (2)	DE602004015614D1 (da)
DK (2)	DK1651621T3 (da)
EA (1)	EA200600203A1 (da)
EC (1)	ECSP066355A (da)
ES (2)	ES2281834T3 (da)
HR (1)	HRP20080559T3 (da)
IL (1)	IL173591A0 (da)
IS (1)	IS8280A (da)
LT (1)	LT5410B (da)
LV (1)	LV13453B (da)
MX (2)	MXPA06001550A (da)
NO (1)	NO20061122L (da)
NZ (1)	NZ545030A (da)
PL (2)	PL1651621T3 (da)
PT (2)	PT1651622E (da)
SG (1)	SG131114A1 (da)
SI (2)	SI1651622T1 (da)
TW (1)	TW200521120A (da)
UA (1)	UA84025C2 (da)
WO (2)	WO2005016897A1 (da)
ZA (1)	ZA200601946B (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL1651621T3 (pl) *	2003-08-08	2009-01-30	Janssen Pharmaceutica Nv	Związki 2-(chinoksalin-5-ylosulfonyloamino)benzamidowe jako modulatory CCK2
WO2005085188A2 (en) *	2004-03-02	2005-09-15	Compass Pharmaceuticals Llc	Compounds and methods for anti-tumor therapy
EP1763524A1 (en) *	2004-04-23	2007-03-21	Takeda San Diego, Inc.	Indole derivatives and use thereof as kinase inhibitors
US7947833B2 (en) *	2004-08-04	2011-05-24	Janssen Pharmaceutica Nv	Preparation of quinoxaline compounds
JP2008514608A (ja)	2004-09-24	2008-05-08	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	スルホンアミド化合物
FR2904317A1 (fr)	2006-07-27	2008-02-01	Inst Nat Sante Rech Med	Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques
US8592565B2 (en) *	2007-01-12	2013-11-26	The Board Of Trustees Of The Leland Stanford Junior University	Preparation of azide-modified carbon surfaces for coupling to various species
WO2008108445A1 (ja)	2007-03-07	2008-09-12	Takeda Pharmaceutical Company Limited	ベンゾオキサゼピン誘導体およびその用途
WO2008124518A1 (en) *	2007-04-03	2008-10-16	Janssen Pharmaceutica N.V.	Oxo-dihydroisoindole sulfonamide compounds as modulators of the cck2 receptor
EP2131243B1 (en) *	2008-06-02	2015-07-01	ASML Netherlands B.V.	Lithographic apparatus and method for calibrating a stage position
WO2009154754A2 (en) *	2008-06-17	2009-12-23	Concert Pharmaceuticals, Inc.	Synthesis of deuterated morpholine derivatives
WO2010118208A1 (en) *	2009-04-09	2010-10-14	Exelixis, Inc.	Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer
EP2486004B1 (en)	2009-10-09	2017-05-03	Zafgen, Inc.	Sulphone compounds for use in the treatment of obesity
EP2590953B1 (en)	2010-07-09	2014-10-29	Convergence Pharmaceuticals Limited	Tetrazole compounds as calcium channel blockers
BR112013001613A2 (pt)	2010-07-22	2016-05-24	Zafgen Inc	compostos tricíclicos e métodos para fazer e usar os mesmos.
WO2012103333A1 (en)	2011-01-26	2012-08-02	Zafgen Corporation	Tetrazole compounds and methods of making and using same
CN103748094B (zh)	2011-05-06	2016-06-29	扎夫根股份有限公司	三环磺酰胺化合物及其制备和使用方法
MX343688B (es)	2011-05-06	2016-11-16	Zafgen Inc	Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso.
EA025526B1 (ru)	2011-05-06	2017-01-30	Зафджен Инк.	Частично насыщенные трициклические соединения и способы их получения и применения
US20120309796A1 (en)	2011-06-06	2012-12-06	Fariborz Firooznia	Benzocycloheptene acetic acids
JP2015509102A (ja)	2012-01-18	2015-03-26	ザフゲン，インコーポレイテッド	三環式スルホン化合物並びにその作製および使用方法
JP6035347B2 (ja)	2012-01-18	2016-11-30	ザフゲン，インコーポレイテッド	三環式スルホンアミド化合物ならびにその作製および使用方法
HUE049728T2 (hu)	2012-03-01	2020-10-28	Allergan Inc	Benzofurán-2-szulfonamid származékok, mint kemokin receptor modulátorok
CN104870433A (zh)	2012-11-05	2015-08-26	扎夫根股份有限公司	三环化合物及其制备方法和用途
JP6169716B2 (ja)	2012-11-05	2017-07-26	ザフゲン，インコーポレイテッド	肝疾患を治療する方法
AU2013337288A1 (en)	2012-11-05	2015-05-21	Zafgen, Inc.	Tricyclic compounds for use in the treatment and/or control of obesity
JP6361168B2 (ja) *	2013-06-17	2018-07-25	Jsr株式会社	液晶配向剤、液晶配向膜、液晶表示素子、液晶表示素子の製造方法、重合体及び化合物
CN103524386B (zh) *	2013-10-24	2016-05-18	江苏鼎龙科技有限公司	2-氨基-4-甲磺酰胺甲基苯甲酸甲酯的制备方法
AU2014352875B2 (en)	2013-11-22	2019-10-24	CL BioSciences LLC	Gastrin antagonists (eg YF476, netazepide) for treatment and prevention of osteoporosis
KR20170016754A (ko) *	2015-08-04	2017-02-14	씨제이헬스케어 주식회사	크로마논 유도체의 신규한 제조방법
CN106565509A (zh) *	2016-11-03	2017-04-19	江苏鼎龙科技有限公司	2‑氨基‑4‑甲氨基苯甲酸甲酯盐酸盐的制备方法
KR101894091B1 (ko)	2018-01-23	2018-08-31	씨제이헬스케어 주식회사	크로마논 유도체의 신규한 제조방법
CN108218806B (zh) *	2018-04-02	2019-03-01	上海馨远医药科技有限公司	一种n-叔丁氧羰基吗啉-3-羧酸的制备方法
CN111285806B (zh) *	2018-12-06	2022-04-15	中国医学科学院药物研究所	吡唑类化合物及其制备方法、用途和药物组合物
CN116675684B (zh) *	2023-08-02	2023-11-07	上海翰森生物医药科技有限公司	含炔基稠环类衍生物拮抗剂、其制备方法和应用
WO2025224201A1 (en)	2024-04-26	2025-10-30	F. Hoffmann-La Roche Ag	Novel process for the synthesis of substituted morpholines and thiomorpholines
CN118878477B (zh) *	2024-05-31	2025-09-23	上海馨远医药科技有限公司	一种手性r或s的3-甲基吗啉的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9200420D0 (en) *	1992-01-09	1992-02-26	James Black Foundation The Lim	Amino acid derivatives
SG52229A1 (en)	1993-08-10	1998-09-28	Black James Foundation	Gastrin and cck receptor ligands
DE69724644D1 (de)	1996-12-10	2003-10-09	Zeria Pharm Co Ltd	1,5-benzodiazepinderivate
DE10121003A1 (de)	2001-04-28	2002-12-19	Aventis Pharma Gmbh	Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10121002A1 (de)	2001-04-28	2002-11-14	Aventis Pharma Gmbh	Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen
DE10128331A1 (de)	2001-06-12	2002-12-19	Aventis Pharma Gmbh	Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
DE10134721A1 (de) *	2001-07-17	2003-02-06	Bayer Ag	Tetrahydrochinoxaline
ITTO20020674A1 (it)	2002-07-26	2004-01-26	Rotta Research Lab	Derivati antranilici ad attivita' anticolecistochininica (anti-cck-1), procedimento per la loro preparazione e loro uso farmaceutico
US6943170B2 (en) *	2002-11-14	2005-09-13	Bristol-Myers Squibb Company	N-cycloalkylglycines as HIV protease inhibitors
PL1651621T3 (pl) *	2003-08-08	2009-01-30	Janssen Pharmaceutica Nv	Związki 2-(chinoksalin-5-ylosulfonyloamino)benzamidowe jako modulatory CCK2
JP2008514608A (ja) *	2004-09-24	2008-05-08	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	スルホンアミド化合物

2004
- 2004-08-04 PL PL04780055T patent/PL1651621T3/pl unknown
- 2004-08-04 EP EP04780056A patent/EP1651622B1/en not_active Expired - Lifetime
- 2004-08-04 SG SG200701706-4A patent/SG131114A1/en unknown
- 2004-08-04 WO PCT/US2004/025154 patent/WO2005016897A1/en not_active Ceased
- 2004-08-04 HR HR20080559T patent/HRP20080559T3/xx unknown
- 2004-08-04 CA CA2534885A patent/CA2534885C/en not_active Expired - Lifetime
- 2004-08-04 ES ES04780056T patent/ES2281834T3/es not_active Expired - Lifetime
- 2004-08-04 PT PT04780056T patent/PT1651622E/pt unknown
- 2004-08-04 AU AU2004265311A patent/AU2004265311A1/en not_active Abandoned
- 2004-08-04 PL PL04780056T patent/PL1651622T3/pl unknown
- 2004-08-04 PT PT04780055T patent/PT1651621E/pt unknown
- 2004-08-04 DK DK04780055T patent/DK1651621T3/da active
- 2004-08-04 CA CA002534887A patent/CA2534887A1/en not_active Abandoned
- 2004-08-04 AT AT04780056T patent/ATE353322T1/de not_active IP Right Cessation
- 2004-08-04 DE DE602004015614T patent/DE602004015614D1/de not_active Expired - Lifetime
- 2004-08-04 DE DE602004004663T patent/DE602004004663T2/de not_active Expired - Lifetime
- 2004-08-04 UA UAA200601931A patent/UA84025C2/ru unknown
- 2004-08-04 DK DK04780056T patent/DK1651622T3/da active
- 2004-08-04 US US10/910,983 patent/US7288651B2/en not_active Expired - Lifetime
- 2004-08-04 SI SI200430245T patent/SI1651622T1/sl unknown
- 2004-08-04 CN CNA2004800290901A patent/CN1863781A/zh active Pending
- 2004-08-04 WO PCT/US2004/025153 patent/WO2005016896A1/en not_active Ceased
- 2004-08-04 MX MXPA06001550A patent/MXPA06001550A/es active IP Right Grant
- 2004-08-04 KR KR1020067002650A patent/KR20060060007A/ko not_active Withdrawn
- 2004-08-04 JP JP2006523230A patent/JP4818110B2/ja not_active Expired - Fee Related
- 2004-08-04 EP EP04780055A patent/EP1651621B1/en not_active Expired - Lifetime
- 2004-08-04 BR BRPI0413449-4A patent/BRPI0413449A/pt not_active IP Right Cessation
- 2004-08-04 AT AT04780055T patent/ATE403650T1/de not_active IP Right Cessation
- 2004-08-04 ES ES04780055T patent/ES2310294T3/es not_active Expired - Lifetime
- 2004-08-04 SI SI200430901T patent/SI1651621T1/sl unknown
- 2004-08-04 AU AU2004265312A patent/AU2004265312B2/en not_active Expired - Fee Related
- 2004-08-04 EA EA200600203A patent/EA200600203A1/ru unknown
- 2004-08-04 US US10/910,925 patent/US7304051B2/en not_active Expired - Lifetime
- 2004-08-04 CN CNA200480029094XA patent/CN1863782A/zh active Pending
- 2004-08-04 JP JP2006523231A patent/JP2007501842A/ja not_active Withdrawn
- 2004-08-04 MX MXPA06001482A patent/MXPA06001482A/es active IP Right Grant
- 2004-08-04 NZ NZ545030A patent/NZ545030A/en unknown
- 2004-08-06 TW TW093123552A patent/TW200521120A/zh unknown
- 2004-08-06 AR ARP040102814A patent/AR045930A1/es not_active Application Discontinuation
2006
- 2006-01-31 IS IS8280A patent/IS8280A/is unknown
- 2006-02-07 IL IL173591A patent/IL173591A0/en unknown
- 2006-02-08 CR CR8229A patent/CR8229A/es unknown
- 2006-02-08 EC EC2006006355A patent/ECSP066355A/es unknown
- 2006-02-08 LV LVP-06-18A patent/LV13453B/en unknown
- 2006-03-07 ZA ZA200601946A patent/ZA200601946B/en unknown
- 2006-03-07 LT LT2006017A patent/LT5410B/lt not_active IP Right Cessation
- 2006-03-08 NO NO20061122A patent/NO20061122L/no not_active Application Discontinuation
2007
- 2007-04-04 CY CY20071100473T patent/CY1106486T1/el unknown
- 2007-12-04 US US11/950,326 patent/US7563895B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
MXPA06001550A (es)	2006-09-04
DE602004015614D1 (de)	2008-09-18
HRP20080559T3 (hr)	2009-01-31
SI1651622T1 (sl)	2007-06-30
PL1651621T3 (pl)	2009-01-30
PL1651622T3 (pl)	2007-07-31
US7304051B2 (en)	2007-12-04
LT2006017A (en)	2006-11-27
JP4818110B2 (ja)	2011-11-16
ATE403650T1 (de)	2008-08-15
ES2310294T3 (es)	2009-01-01
ATE353322T1 (de)	2007-02-15
KR20060060007A (ko)	2006-06-02
CA2534887A1 (en)	2005-02-24
NZ545030A (en)	2009-08-28
PT1651622E (pt)	2007-04-30
US20050038032A1 (en)	2005-02-17
EP1651622A1 (en)	2006-05-03
CA2534885A1 (en)	2005-02-24
WO2005016897A1 (en)	2005-02-24
UA84025C2 (en)	2008-09-10
CA2534885C (en)	2013-06-04
LT5410B (lt)	2007-03-26
EP1651621B1 (en)	2008-08-06
US7288651B2 (en)	2007-10-30
LV13453B (en)	2007-02-20
CY1106486T1 (el)	2012-01-25
DE602004004663T2 (de)	2007-11-22
IL173591A0 (en)	2006-07-05
NO20061122L (no)	2006-05-04
DE602004004663D1 (de)	2007-03-22
SI1651621T1 (sl)	2008-12-31
TW200521120A (en)	2005-07-01
EA200600203A1 (ru)	2006-08-25
CN1863782A (zh)	2006-11-15
CR8229A (es)	2008-09-10
WO2005016896A1 (en)	2005-02-24
ES2281834T3 (es)	2007-10-01
MXPA06001482A (es)	2006-09-04
AU2004265312A1 (en)	2005-02-24
US20080076918A1 (en)	2008-03-27
ECSP066355A (es)	2006-08-30
US20050043310A1 (en)	2005-02-24
IS8280A (is)	2006-01-31
BRPI0413449A (pt)	2006-10-17
SG131114A1 (en)	2007-04-26
CN1863781A (zh)	2006-11-15
ZA200601946B (en)	2007-05-30
JP2007501841A (ja)	2007-02-01
AR045930A1 (es)	2005-11-16
US7563895B2 (en)	2009-07-21
EP1651621A1 (en)	2006-05-03
JP2007501842A (ja)	2007-02-01
AU2004265311A1 (en)	2005-02-24
AU2004265312B2 (en)	2010-05-20
PT1651621E (pt)	2008-09-30
DK1651621T3 (da)	2008-11-10
EP1651622B1 (en)	2007-02-07

Publication	Publication Date	Title
DK1651622T3 (da)	2007-05-07	Fremgangsmåde til fremstilling af 2-(quinoxalin-5-ylsulfonylamino)-benzamidforbindelser
DK1828164T3 (da)	2008-12-08	Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1778668T3 (da)	2013-09-30	Fremgangsmåde til fremstilling af dihydropteridion
DK1611108T3 (da)	2011-10-10	Fremgangsmåde til fremstilling af telmisartan
DK1854454T3 (da)	2014-01-13	Fremgangsmåde til fremstilling af amorf telmisartan
DK1893586T3 (da)	2009-01-05	Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler
DK1840125T3 (da)	2009-11-09	Mellemprodukter til fremstilling af dioxan-2-alkylcarbamater
DK1546122T3 (da)	2008-03-03	Fremgangsmåde til fremstilling af valsartan
DK1380121T3 (da)	2007-12-27	Fremgangsmåde til fremstilling af oxazolidinoner
DK1567482T3 (da)	2010-05-17	Fremgangsmåde til fremstilling af phenylmalonsyre-dinitriler
DK1407037T3 (da)	2006-05-22	Fremgangsmåde til fremstilling af tagatose
DK1578731T3 (da)	2010-02-15	Fremgangsmåde til fremstilling af pyrimidinforbindelser
DK1678135T3 (da)	2009-09-07	Fremgangsm de til fremstilling af n-amino-substituerede hetorocykliske forbindelser
DK1756049T3 (da)	2008-02-25	Fremgangsmåde til fremstilling af 1,4-diphenylazetidinon-derivater
DK1575941T3 (da)	2012-07-09	Fremgangsmåde til fremstilling af (S)-pantoprazol
DK1572613T3 (da)	2006-12-18	Fremgangsmåde til fremstilling af benzophenoner
DK1519928T3 (da)	2014-08-04	Fremgangsmåde til fremstilling af heterocykliske fluoralkenylsulfoner
DK1682541T3 (da)	2010-06-28	Fremgangsmåde til fremstilling af tiotropiumsalte
DK1831223T3 (da)	2013-06-10	Fremgangsmåde til fremstilling af L-biopterin
DK1963251T3 (da)	2012-11-26	Fremgangsmåde til fremstilling af aminer
DK1660485T3 (da)	2007-03-19	Forbedret fremgangsmåde til fremstilling af alpha-polymorfisk eletriptanhydrobromid
DK1692137T3 (da)	2007-04-30	Fremgangsmåde til fremstilling af tubulinininhibitorer
DK1805316T3 (da)	2009-08-10	Fremgangsmåde til fremstilling af de enantiomere former af cis-3-hydroxycy-
DK1511724T3 (da)	2014-06-16	Fremgangsmåde til fremstilling af thioalkylaminderivater
DK1519936T3 (da)	2008-03-03	Fremgangsmåde til fremstilling af nevirapin